10-Q: Clover Health Reports Strong Revenue Growth and Profitability Turnaround

Clover Health Investments, Corp. announced a substantial increase in total revenues and a significant swing to net income for the six months ended June 30, 2026, driven by membership growth and improved per-member premiums.

Summary

• Clover Health reported total revenues of $743.2 million for Q2 2026, a 55.6% increase year-over-year, and $1.49 billion for the first six months of 2026, a 59.9% increase.
• The company achieved income from operations of $28.0 million in Q2 2026 and $55.3 million for the first six months of 2026, a significant improvement from net losses in the prior year periods.
• Adjusted SG&A as a percentage of total revenues improved to 15.5% for the first six months of 2026 from 17.6% in the prior year.
• Adjusted EBITDA increased to $81.2 million for the first six months of 2026, up from $42.9 million in the prior year.
• The company maintained a strong liquidity position with $443.0 million in cash, cash equivalents, and investments as of June 30, 2026.
• CMS recalculated the 2026 Star Ratings for Clover's PPO and HMO plans to 4.5 Stars for payment year 2027, impacting future payments.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing positively due to significant revenue growth, a shift from net loss to net income, and improved operational efficiency metrics, despite ongoing investments in growth and administrative costs.

Positives

• Total revenues increased by 57.0% to $737.8 million for Q2 2026 and by 59.9% to $1.48 billion for the first six months of 2026.
• Shift from a net loss of $10.6 million in Q2 2025 to a net income of $28.0 million in Q2 2026.
• Income from operations turned positive, reaching $28.0 million in Q2 2026 and $55.3 million for the first six months of 2026.
• Average membership grew by approximately 49% in Q2 2026 and 50% in the first six months of 2026.
• Per-member premium increased by approximately 6% in Q2 2026 and 7% in the first six months of 2026, partly due to improved Star Ratings.
• Adjusted SG&A as a percentage of total revenues improved from 17.3% in Q2 2025 to 15.1% in Q2 2026, and from 17.6% to 15.5% for the six-month periods.
• Adjusted EBITDA increased by 139% to $40.9 million in Q2 2026 and by 89% to $81.2 million for the first six months of 2026.
• CMS recalculated Star Ratings for PPO and HMO plans to 4.5 Stars for payment year 2027, which is expected to positively impact future revenue.

Negatives

• General and administrative expenses increased by 45.0% to $70.3 million in Q2 2026 and by 46.2% to $144.9 million for the first six months of 2026.
• Net medical claims incurred increased by 56.1% to $590.2 million in Q2 2026 and by 61.3% to $1.18 billion for the first six months of 2026, largely due to membership growth.
• Per-member medical costs increased by approximately 5% in Q2 2026 and 7% in the first six months of 2026.
• Other income decreased by 30.7% in Q2 2026 and 21.3% for the six-month period, primarily due to the absence of a non-recurring gain and lower investment income.
• The company is facing multiple putative class action lawsuits related to a cybersecurity incident disclosed on July 17, 2026.

Risks

• The company's failure to protect its sites, networks, and systems against security breaches could damage its reputation and substantially harm its business.
• Cybersecurity threats are increasing in frequency, sophistication, and intensity, with threat actors using advanced technologies like AI.
• A cybersecurity incident could result in regulatory investigations, litigation, indemnification obligations, and significant financial and operational costs.
• Vulnerabilities in third-party service providers' systems or failures in their safeguards could also harm the company's business.
• The company faces ongoing litigation risk, including class action complaints stemming from a recent cybersecurity incident.
• Changes in government healthcare policy, including the ACA and rules related to Medicare and medical loss ratios, could negatively affect revenue and profit margins.
• The company's ability to maintain or improve its Star Ratings could impact its financial performance.
• Fluctuations in the price of its Class A common stock and continued compliance with Nasdaq's listing requirements are ongoing concerns.

Future Outlook

The company expects its current cash, cash equivalents, and investments, along with projected cash flows, to be sufficient for the next 12 months. Future capital requirements will depend on business growth, opportunities, and unforeseen circumstances, potentially requiring additional equity or debt financing.

Management Comments

• Our results reflect continued membership growth alongside disciplined management of administrative spend.
• We believe that the presentation of such metrics is useful to management and counterparties to model the performance of healthcare companies such as Clover.
• We believe our BER is useful to management, investors, and others because it offers a clearer and more accurate representation of our investment in healthcare quality and member engagement.

Industry Context

StockSavvy.ai notes that Clover Health's performance aligns with broader trends in the Medicare Advantage market, characterized by increasing membership and a focus on technology-driven care management. The company's strategic expansion of its technology platform to external payors and providers via Counterpart Health, Inc. reflects a growing industry trend towards value-based care enablement and SaaS solutions in healthcare.

Comparison to Industry Standards

• Clover Health's total revenues for the six months ended June 30, 2026, of $1.49 billion represent significant growth, outpacing many smaller health insurers.
• The company's shift to profitability, with $55.3 million in income from operations for the six months ended June 30, 2026, contrasts with the historical losses of some emerging health tech companies.
• The improved Adjusted SG&A as a percentage of total revenues (15.5%) indicates increasing operational leverage, a key benchmark for efficiency in the managed care industry.
• The 4.5 Star Ratings achieved for payment year 2027 are competitive within the Medicare Advantage landscape, where higher ratings translate to better bonus payments and marketability.
• The company's focus on technology, particularly Clover Assistant, is a differentiator, though many competitors are also investing heavily in digital health solutions and data analytics.

Legal Proceedings

• Multiple putative class action complaints filed in the U.S. District Court for the Middle District of Tennessee (July 2026) arising from a cybersecurity incident disclosed on July 17, 2026, alleging compromise of PII and PHI.
• The company is vigorously defending these matters and cannot reasonably estimate the possible loss or range of loss at this early stage.

Related Party Transactions

• Contract with Medical Records Exchange, LLC (Credo) for administrative services, where Vivek Garipalli (Executive Chairman) is an indirect owner.
• Contract with Thyme Care, Inc. for oncology care management services, where Vivek Garipalli is a board member and holds a less than 5% equity interest.
• Agreement with Guidehealth, LLC for value-based care enablement and outsourced administrative services, where Thomas Tran (Board Member) serves as a director and holds a less than 5% ownership interest. The agreement has been terminated.
• Master Services Agreement with GoldenScript, Inc. for administrative and clinical management services, where GoldenScript is approximately 25% owned by Wormhole Capital, an entity affiliated with Vivek Garipalli.

Stakeholder Impact

• Shareholders: Positive impact from revenue growth, improved profitability, and potential future benefits from higher Star Ratings. Potential negative impact from ongoing litigation and cybersecurity risks.
• Members: Continued access to Medicare Advantage plans with a focus on technology-enabled care. Potential impact from cybersecurity incident if their PII/PHI was compromised.
• Providers: Continued access to Clover Assistant platform for patient management and insights. Potential for increased engagement through Counterpart Assistant.
• Employees: Continued focus on growth and technology development. Potential impact from stock-based compensation adjustments and company performance.
• Creditors: Strong liquidity position and positive operating cash flow provide comfort regarding debt obligations.

Next Steps

• Continue to grow Medicare Advantage membership and expand provider networks.
• Leverage Clover Assistant and Counterpart Assistant technology for improved care and cost management.
• Monitor and respond to evolving regulatory environments and CMS Star Rating requirements.
• Continue to manage administrative spend and operational efficiency.
• Address ongoing legal proceedings related to the cybersecurity incident.

Key Dates

Recommendation

While the company shows strong revenue growth and a positive turn to profitability, the increase in administrative expenses, ongoing litigation from a cybersecurity incident, and the inherent risks in the healthcare industry warrant a cautious approach. The improved Star Ratings are a positive catalyst, but the full impact of the cybersecurity litigation and the company's ability to sustain operational improvements need further observation.

Keywords

Medicare Advantage, Health Insurance, Healthcare Technology, Clover Assistant, Star Ratings, Medical Claims, Revenue Growth, Financial Performance